Ruthenium(II) Porphyrin Catalyzed Formation of (Z)-4-Alkyloxycarbonyl- methylidene-1,3-dioxolanes from γ-Alkoxy-α-diazo-β-ketoesters
摘要:
[GRAPHICS]Ruthenum(II) porphyrins and dirhodium(II) acetate catalyze cyclization of gamma-alkoxy-alpha-diazo-beta-ketoesters to (Z)-4-(alkyloxycarbonylmethylidene)-1,3-dioxolanes selectively (ca. 68% yield) with no formation of 3(2H)-furanones. Reacting a diazo ketoester with [Ru-II(TTP)(CO)] [H2TTP = meso-tetrakis(p-tolyl) porphyrin] in toluene afforded a ruthenium carbenoid complex, which has been isolated and spectroscopically characterized. A mechanism involving hydrogen atom migration from the C-H bond to the ruthenium carbenoid is proposed.
Ruthenium(II) Porphyrin Catalyzed Formation of (Z)-4-Alkyloxycarbonyl- methylidene-1,3-dioxolanes from γ-Alkoxy-α-diazo-β-ketoesters
摘要:
[GRAPHICS]Ruthenum(II) porphyrins and dirhodium(II) acetate catalyze cyclization of gamma-alkoxy-alpha-diazo-beta-ketoesters to (Z)-4-(alkyloxycarbonylmethylidene)-1,3-dioxolanes selectively (ca. 68% yield) with no formation of 3(2H)-furanones. Reacting a diazo ketoester with [Ru-II(TTP)(CO)] [H2TTP = meso-tetrakis(p-tolyl) porphyrin] in toluene afforded a ruthenium carbenoid complex, which has been isolated and spectroscopically characterized. A mechanism involving hydrogen atom migration from the C-H bond to the ruthenium carbenoid is proposed.
Pyrimidine derivatives as IL-8 receptor antagonists
申请人:——
公开号:US20040087601A1
公开(公告)日:2004-05-06
Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula I
1
In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, —O—alkyl or —S-alkyl. A representative example is:
2
[EN] PYRIMIDINE DERIVATIVES AS IL-8 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRIMIDINE UTILISES COMME ANTAGONISTES DES RECEPTEURS DE L'IL-8
申请人:PHARMACOPEIA INC
公开号:WO2004062609A2
公开(公告)日:2004-07-29
Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula (I). In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, -O-alkyl or -S-alkyl. A representative example is formula (X).
Ruthenium(II) Porphyrin Catalyzed Formation of (<i>Z</i>)-4-Alkyloxycarbonyl- methylidene-1,3-dioxolanes from <i>γ</i>-Alkoxy-<i>α</i>-diazo-<i>β</i>-ketoesters
作者:Shi-Long Zheng、Wing-Yiu Yu、Chi-Ming Che
DOI:10.1021/ol010283f
日期:2002.3.1
[GRAPHICS]Ruthenum(II) porphyrins and dirhodium(II) acetate catalyze cyclization of gamma-alkoxy-alpha-diazo-beta-ketoesters to (Z)-4-(alkyloxycarbonylmethylidene)-1,3-dioxolanes selectively (ca. 68% yield) with no formation of 3(2H)-furanones. Reacting a diazo ketoester with [Ru-II(TTP)(CO)] [H2TTP = meso-tetrakis(p-tolyl) porphyrin] in toluene afforded a ruthenium carbenoid complex, which has been isolated and spectroscopically characterized. A mechanism involving hydrogen atom migration from the C-H bond to the ruthenium carbenoid is proposed.